Bulletin
Investor Alert

June 10, 2020, 7:29 a.m. EDT

Magic Mushrooms and LSD May be Top Gateway Drugs for Treating Eating Disorders

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Yield Growth Corp. (BOSS)

or Cancel Already have a watchlist? Log In

Houston, Texas, Jun 10, 2020 (Newsfile Corp via COMTEX) -- Houston, Texas--(Newsfile Corp. - June 10, 2020) - Psychedelics could rapidly change the way we address obesity and eating disorders.

We already know that major institutions have found such drugs can effectively treat obsessive-compulsive disorder, PTSD, opioid addiction, alcoholism, depression, and anxiety.

Nowadays, we may soon learn they can assist with obesity and eating disorders, too.

That's because psilocybin activates serotonin receptors, or "nature's own appetite suppressant," as noted by Psychology Today. "This powerful brain chemical curbs cravings and shuts off appetite. It makes you feel satisfied even if your stomach is not full. The result is eating less and losing weight."

We may also soon learn LSD may be useful in treating those issues, as well.

Doctors first used LDS to treat issues such as anxiety and depression during the 1950s and 1960s, says Vice.com. While the drug has since been written off, it may soon make a comeback to also help with obesity and eating disorders as well. That's what Yield Growth Corp. /zigman2/quotes/202014329/delayed CA:BOSS 0.00% (otcqb:BOSQF) majority owned subsidiary NeonMind has set out to prove.

NeonMind: LSD Could Assist in the Treatment of Obesity and Eating Disorders

NeonMind has filed an additional provisional patent application related to using psychedelics as medicine. The patent application covers the administration of a compound selected from the group consisting of lysergic acid diethylamide and d-lysergic acid amide (and compounds with similar molecular structure)in combination with a 5-HT2A antagonist to treat compulsive eating disorder, obesity and related illnesses.

The patent application was filed by NeonMind on June 5, 2020, and Translational Life Sciences Inc. has a 20% interest as a co-collaborator on the development of intellectual property. "Our research with our scientific team into using psilocybin to treat compulsive eating and food cravings has led to paths of inquiry for research into expanded medical uses of psychedelics," says Penny White, NeonMind CEO, "we are excited to lay the groundwork for new areas of potential research for the future."

The global projected market for weight loss and weight management treatment is estimated at USD $245 billion, according to MarketsandMarkets. The global projected market for diabetes treatment is estimated at $87 billion US Dollars, according to Modor Intelligence.

Research and development involving controlled substances such as psilocybin, LSD and LSA in Canada can only be conducted with approval by Health Canada. Section 56 of the Controlled Drug and Substances Act (Canada) grants Health Canada the right to give exemptions for research into controlled substances.

NeonMind: Psilocybin Could be a Weight Loss Secret

In addition, majority owned subsidiary NeonMind just filed a U.S. provisional patent application in the United States for the invention relating to therapeutic administration of psilocybin or psilocin (or analogs thereof) combined with supportive therapeutic treatment for a patient to provide weight loss benefits and treatment for related health issues.

The provisional patent is for a proposed guided psychedelic psilocybin therapy protocol using psychotherapy prior to, during and after the psychoactive effects of the Psilocybin are felt by the patient. The psychedelic assisted psychotherapy is designed to assist in gaining insights from positive psychedelic experiences, to be integrated into everyday life and to help plan, prepare and make sense of psychedelic experiences for a therapeutic result. It can include an exploration of unresolved issues in the patient's life that are embedded in his or her subconscious, including discussions or examinations of pain. It may also include building self-esteem, the patient taking responsibility for his or her own condition, self empowerment, and acknowledging or releasing any unhealthy self defence mechanism of overeating.

NeonMind previously announced that it filed a provisional patent in December 2019 for the use of microdose administration of Psilocybin for weight loss benefits. NeonMind has retained contract research organization Translational Life Sciences Inc. to design and plan an initial preclinical study using psilocybin which is anticipated to begin in the fall of 2020. The preclinical study is anticipated to provide data to design phase 2 human clinical trials to test Psilocybin as a weight loss treatment. The phase 2 clinical trials are anticipated to begin in 2021, subject to receiving all required regulatory approvals.

NeonMind's combined provisional patent applications cover the administration of Psilocybin to provide weight loss benefits and potential treatment or regulation of diabetes, and regulation of blood glucose, and to reduce susceptibility to cardiovascular disease, high blood pressure, diabetes mellitus, hypertension, multiple sclerosis, erectile dysfunction, urinary incontinence, chronic renal failure, sleep apnea, asthma, and certain forms of cancer.

For more information, visit the company's website at https://yieldgrowth.com .

About MarijuanaStox

MarijuanaStox.com is a leading web destination for all cannabis related companies. Investors can also find current marijuana-related quality financial, medical, legal and social news. MarijuanaStox.com is a media agency in North America dedicated to the cannabis industry, helping companies that operate in the space to attract quality investors, working capital and real publicity. Since 2005, we have had public companies in the US and Canada have rely on us to grow and succeed.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media which has a partnership with www.MarijuanaStox.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.

For making specific investment decisions, readers should seek their own advice. Winning Media, which has a partnership with www.MarijuanaStox.com , is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement between Winning Media (partners of MarijuanaStox.com) and The Yield Growth Corp, Winning Media has been paid four thousand dollars for advertising and marketing services for The Yield Growth Corp. We own ZERO shares of The Yield Growth Corp. Please click here for full disclaimer.

Contact Information:
2818047972
ty@marijuanastox.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/57594

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

copyright (c) newsfile corp. 2020. all rights reserved

/zigman2/quotes/202014329/delayed
CA : Canadian Securities Exchange
$ 0.10
0.00 0.00%
Volume: 137,227
Aug. 7, 2020 2:08p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$13.57 million
Rev. per Employee
N/A
loading...

This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.